1 Change in LBP pain intensity from baseline on 100 mm VAS, follow‐up <= 3 weeks |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
1.1 Meloxicam |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.2 Lornoxicam |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 Global improvement |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
2.1 Diclofenac |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Side effects |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
3.1 Meloxicam 7.5/15mg vs. Diclofenac 150mg |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.2 Lornoxicam |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Number of participants with additional pain medication |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
4.1 Meloxicam 7.5/15mg vs. Diclofenac |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |